Levetiracetam

左乙拉西坦

Report date: 2026/04/10 20:01:49
NMEFirst In Class

Base Information

Drug NameLevetiracetam
Drug Alias NameLevetiracetamum左旋乙拉西坦Levetiracetam IRLevetiracetam XREKeppra +[21] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSynaptic vesicle glycoprotein 2A modulators
TargetsSynaptic vesicle glycoprotein 2A
Therapy Area/IndicationsBrain metastasesSolid tumoursLevodopa-induced dyskinesia +[49] 
Global Approved IndicationsSeizuresEpilepsy
Approved Indications in ChinaEpilepsy
Original Approved Country/TerritoryUnited States
Original Approved Date1999/11/30
Country/TerritoryCzechiaBelgiumBulgaria +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUcb Sa
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteMubadala Investment CompanyCBC Co Ltd +[22] 
Inactive CompaniesLudwig Maximilians University Of MunichUniversity Of MinnesotaUniversity Of Rochester +[23] 
Active IndicationsBrain metastasesSolid tumoursSchizophrenia +[22] 
Inactive IndicationsLevodopa-induced dyskinesiaStress Disorders, Post-TraumaticBipolar Disorder +[27] 

Other Information

ATC CodeN03AX14
Related LinksWikipediaDrugBankKEGG